跳至主要内容
临床试验/IRCT2016050717413N15
IRCT2016050717413N15已完成2 期

Effect of Combination Therapy with Ledipasvir and Sofosbuvir (Hepasbuvir Plus) with or without Ribavirin for Treatment of Iranian Patients with Genotype-1 Hepatitis C Virus Infection

Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Med0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Inclusion Criteria: Iranian patients with genotype-1 hepatitis C virus infection; with minimum age of 18 year old; with or without previous history of treatment (Peg-Interferon, Ribavirin, Protease inhibitors including: Telaprevir and Boceprevir); Compensated or Decompensated Cirrhosis;

排除标准

  • Co-infection with HIV infection; Patients with thalassemia; Patients with hemophilia; Patients with history of chronic hemodialysis; patients with history of liver transplantation

研究者

发起方
Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Med

相似试验